Press Releases

Date Title and Summary Additional Formats
Toggle Summary Retrophin Reports First Quarter 2018 Financial Results
Company obtains FDA and EMA feedback on pathway to NDA and MAA filing for sparsentan in IgA nephropathy; single Phase 3 trial expected to initiate in the fourth quarter of 2018 Pivotal Phase 3 DUPLEX Study of sparsentan in FSGS underway to support Subpart H NDA filing Revenue rose 14 percent to $38
View HTML
Toggle Summary Retrophin to Report First Quarter 2018 Financial Results
SAN DIEGO , April 17, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced it will report first quarter 2018 financial results on Tuesday, May 1, 2018 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial
View HTML
Toggle Summary Retrophin Initiates Pivotal Phase 3 Clinical Trial of Sparsentan for the Treatment of Focal Segmental Glomerulosclerosis
SAN DIEGO , April 03, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced that the first patient has been enrolled in the DUPLEX Study, a global, pivotal Phase 3 clinical trial evaluating the long-term nephroprotective potential of sparsentan for the treatment of focal segmental
View HTML
Toggle Summary Retrophin Announces Appointment of Casey Logan as Vice President of Corporate Development
SAN DIEGO , March 05, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced that Casey Logan has joined the Company as vice president, corporate development. Mr. Logan will report to chief operating officer Neil McFarlane , and be responsible for leading global corporate and
View HTML
Toggle Summary Retrophin to Present at the Barclays Global Healthcare Conference
SAN DIEGO , Feb. 28, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced that Stephen Aselage , chief executive officer, will present at the Barclays Global Healthcare Conference in Miami on Wednesday, March 14, 2018 at 3:50 p.m. ET .
View HTML
Toggle Summary Retrophin Recognizes Rare Disease Day® 2018 and Joins Others Worldwide to Raise Awareness About Rare Diseases View HTML
Toggle Summary Retrophin Reports Fourth Quarter and Full Year 2017 Financial Results
Company gains alignment to proceed on Subpart H accelerated approval pathway for sparsentan in FSGS; Study start-up activities ongoing to initiate Phase 3 pivotal trial in second quarter of 2018 Clinical development of sparsentan in IgAN and CNSA-001 in PKU expected to initiate in 2018 Revenue
View HTML
Toggle Summary Retrophin to Report Fourth Quarter and Full Year 2017 Financial Results
SAN DIEGO , Feb. 13, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced it will report fourth quarter and full year 2017 financial results on Tuesday, February 27, 2018 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss
View HTML
Toggle Summary Retrophin to Present at the Leerink Partners 7th Annual Global Healthcare Conference
SAN DIEGO , Feb. 01, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced that Stephen Aselage , chief executive officer, will present at the Leerink Partners 7th Annual Global Healthcare Conference in New York City on Thursday, February 15, 2018 at 9:00 a.m. ET .
View HTML
Toggle Summary Retrophin Gift to Establish Rare Disease Network at Children’s National View HTML